KROS

Keros Therapeutics, Inc.

Stock · NASDAQ

Program summary

FieldValueAs ofSource
Current authorization$10m16-Nov-268-K filed 16-Nov-26
Remaining authorization$8mEST16-Nov-268-K filed 16-Nov-26
Program expiry28-Feb-2730-Sep-2610-Q filed 05-Nov-26
Repurchased last quarter$2m30-Sep-2610-Q filed 05-Nov-26
Has used an ASRNo—

Remaining authorization is estimated: we derive it from reported spend, or convert a share authorization at the latest close. Check the linked filings.

Programs

Authorized onAuthorizedRemainingExpiresTerms
16-Nov-26$5m$5mESTn/aStock repurchase program for up to $5 million of common stock following receipt of $20 million development milestone payment from Takeda8-K filed 16-Nov-26
08-Sep-26$5m$3m28-Feb-27On September 8, 2026, our board of directors authorized a stock repurchase program to repurchase up to $5.0 million of our common stock from time to time prior to February 28, 2027 (the “September 2026 Repurchase Program”).10-Q filed 05-Nov-26

Open-market repurchases

Repurchased per month, USD (≈ shares × average price)
  1. Jul ’26
  2. Aug ’26
  3. ≈$2m
    Sep ’26
Month endedSharesAvg price≈ ValueSource
30-Sep-26146,342$11.27$2m10-Q filed 05-Nov-26
31-Aug-260—$010-Q filed 05-Nov-26
31-Jul-260—$010-Q filed 05-Nov-26
Filings through 16-Nov-26· checked 18-Nov-26